NVCN Neovasc Inc

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):           

            Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):           

DOCUMENT 1

Neovasc Inc. Reports Results of Annual General and Special Meeting of Shareholders

NASDAQ, TSX: NVCN

VANCOUVER, June 4, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) is pleased to announce the results of the votes on matters considered at its Annual General and Special Meeting of Shareholders held on June 4, 2018 in Vancouver, B.C. (the "Meeting").

At the Meeting, the shareholders of the Company (the "Shareholders") re-elected board members Alexei Marko, Paul Geyer, Dr. Jane Hsiao, Steven Rubin, Dr. William O'Neill, and Doug Janzen to serve in office until the next annual meeting or until their successors are duly elected or appointed. Detailed results of the voting in respect of the election of directors are as follows:

At the Meeting, the Shareholders also approved amendments to the Company's stock option plan and the unallocated options thereunder (91.69% of votes cast in favour), approved the Company's Common Share Consolidation (83.84% of votes cast in favour) and re-appointed Grant Thornton LLP, Chartered Accountants as auditors of the Company (94.81% of votes cast in favour).

As of May 31, 2018, a total of 1,860,184,719 Common Shares were issued and outstanding.

About Neovasc Inc.  

Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Reducer, for the treatment of refractory angina, which is not currently available in the United States and has been available in Europe since 2015, and the Tiara, for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada and Europe. For more information, visit: www.neovasc.com.  

View original content:http://www.prnewswire.com/news-releases/neovasc-inc-reports-results-of-annual-general-and-special-meeting-of-shareholders-300659450.html

SOURCE Neovasc Inc.

View original content: http://www.newswire.ca/en/releases/archive/June2018/04/c8215.html

%CIK: 0001399708

For further information: Investor Relations, Neovasc Inc., Chris Clark, 604 248-4138, cclark@neovasc.com

CO: Neovasc Inc.

CNW 17:38e 04-JUN-18

Neovasc (NASDAQ:NVCN)
Historical Stock Chart
From Jun 2024 to Jul 2024

Neovasc (NASDAQ:NVCN)
Historical Stock Chart
From Jul 2023 to Jul 2024